424 related articles for article (PubMed ID: 32307022)
1. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I/II trial.
Nour Y; Pöttgen C; Kebir S; Lazaridis L; Lüdemann L; Guberina M; Gauler T; Scheffler B; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Glas M; Lübcke W; Stuschke M; Guberina N
J Appl Clin Med Phys; 2021 Jan; 22(1):242-250. PubMed ID: 33389825
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.
Ballo MT; Urman N; Lavy-Shahaf G; Grewal J; Bomzon Z; Toms S
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1106-1113. PubMed ID: 31026557
[TBL] [Abstract][Full Text] [Related]
4. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study.
Straube C; Oechsner M; Kampfer S; Scharl S; Schmidt-Graf F; Wilkens JJ; Combs SE
Radiat Oncol; 2018 Feb; 13(1):31. PubMed ID: 29471879
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric Impact of a Tumor Treating Fields Device for Glioblastoma Patients Undergoing Simultaneous Radiation Therapy.
Li T; Shukla G; Peng C; Lockamy V; Liu H; Shi W
Front Oncol; 2018; 8():51. PubMed ID: 29594036
[TBL] [Abstract][Full Text] [Related]
7. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
8. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
9. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
[TBL] [Abstract][Full Text] [Related]
10. Targeting Accuracy Considerations for Simultaneous Tumor Treating Fields Antimitotic Therapy During Robotic Hypofractionated Radiation Therapy.
Biswas S; Kapitanova I; Divekar S; Grimm J; Butterwick IJ; Garren D; Kleinberg LR; Redmond KJ; Lacroix M; Mahadevan A; Forster KM
Technol Cancer Res Treat; 2021; 20():15330338211039135. PubMed ID: 34632866
[No Abstract] [Full Text] [Related]
11. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
Ali AS; Lombardo J; Niazi MZ; Miller RC; Alnahhas I; Martinez NL; Andrews DW; Judy KD; Shi W
J Neurooncol; 2022 Nov; 160(2):345-350. PubMed ID: 36355259
[TBL] [Abstract][Full Text] [Related]
13. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
14. Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.
Jiang P; Zhang X; Wei S; Zhao T; Wang J
J Appl Clin Med Phys; 2020 Apr; 21(4):22-30. PubMed ID: 32170991
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric impact of respiratory motion, interfraction baseline shifts, and anatomical changes in radiotherapy of non-small cell lung cancer.
Schmidt ML; Hoffmann L; Kandi M; Møller DS; Poulsen PR
Acta Oncol; 2013 Oct; 52(7):1490-6. PubMed ID: 23905673
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy, coplanar volumetric-modulated arc, therapy, and noncoplanar volumetric-modulated arc therapy in, glioblastoma: A dosimetric comparison.
Hou Y; Zhang Y; Liu Z; Yv L; Liu K; Tian X; Lv Y
Clin Neurol Neurosurg; 2019 Dec; 187():105573. PubMed ID: 31706107
[TBL] [Abstract][Full Text] [Related]
17. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
[TBL] [Abstract][Full Text] [Related]
18. Noncoplanar VMAT for Brain Metastases: A Plan Quality and Delivery Efficiency Comparison With Coplanar VMAT, IMRT, and CyberKnife.
Zhang S; Yang R; Shi C; Li J; Zhuang H; Tian S; Wang J
Technol Cancer Res Treat; 2019 Jan; 18():1533033819871621. PubMed ID: 31451059
[TBL] [Abstract][Full Text] [Related]
19. Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations.
Korshoej AR; Hansen FL; Mikic N; von Oettingen G; Sørensen JCH; Thielscher A
PLoS One; 2018; 13(8):e0201957. PubMed ID: 30133493
[TBL] [Abstract][Full Text] [Related]
20. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
